Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation
- Status
- COMPLETED
- Phase
- PHASE2
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma
- Status
- TERMINATED
- Phase
- PHASE3
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia
- Status
- TERMINATED
- Phase
- PHASE2
Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia
- Status
- TERMINATED
- Phase
- PHASE1
Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2